Physician profile
Mohsin Ijaz
NPI 1497728760
$9,682.85
in general payments reported to CMS, 2019-2025
37 companies · $1,114 in 2025
The $1,114 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,848 · 2020: $1,047 · 2021: $1,361 · 2022: $1,494 · 2023: $1,209 · 2024: $1,609 · 2025: $1,114.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,838 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,838.25 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,341.19 | 2019-2025 | |
| Philips North America LLC | $806.46 | 2019-2025 | (Ck4) Mcot, Mcot, Extended Holter |
| Merck Sharp & Dohme LLC | $699.15 | 2021-2025 | Verquvo |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $636.07 | 2019-2025 | Lifevest |
| Amgen INC. | $628.50 | 2019-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $559.69 | 2019-2024 | Xarelto |
| Medtronic, INC. | $506.42 | 2021-2024 | Micra, Venaseal |
| Boehringer Ingelheim Pharmaceuticals, INC. | $482.05 | 2020-2025 | Jardiance, Ofev |
| Cook Medical LLC | $466.92 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $420.08 | 2019-2025 | Camzyos, Eliquis |
| Pfizer INC. | $417.61 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $277.96 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $267.62 | 2019-2025 | Brilinta, Wainua |
| Baxter Healthcare | $254.04 | 2023-2024 | Hillrom - Carnation Ambulatory Monitor, Hillrom - Cardiac Ambulatory Monitor |
| Atricure, INC. | $200.04 | 2022-2024 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohsin Ijaz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.